REVIVED-BCIS2
REVascularization for Ischemic VEntricular Dysfunction — British Cardiovascular Intervention Society-2
Paciente / Población Intervención / Exposición Comparación Desenlace
In 700 patients with ischaemic LV dysfunction (LVEF ≤35%) and viable myocardium, PCI plus optimal medical therapy did not reduce all-cause death or HF hospitalisation compared with optimal medical therapy alone.
N
700
Diseño
Multicentre open-label RCT
Desenlace
Death from any cause or hospitalisation for heart failure
Relevancia
2
ResultadoPCI 37.2% vs optimal medical therapy 38.0% (HR 0.99, 95% CI 0.78-1.27, P=0.96); neutral, with no difference in LVEF or quality of life. Median follow-up 41 months.
Perera D, et al. N Engl J Med. 2022;387(15):1351-60. 10.1056/NEJMoa2206606
Discusión y crítica
Enrolled largely stable, minimally symptomatic patients selected for viability. Alongside STICH and ISCHEMIA, challenged the viability-guided revascularisation paradigm and downgraded routine PCI for ischaemic cardiomyopathy.